Last reviewed · How we verify

DEN vaccine F17

U.S. Army Medical Research and Development Command · Phase 1 active Biologic

DEN vaccine F17 is a Biologic drug developed by U.S. Army Medical Research and Development Command. It is currently in Phase 1 development. Also known as: Live attenuated tetravalent dengue (DEN) vaccine.

At a glance

Generic nameDEN vaccine F17
Also known asLive attenuated tetravalent dengue (DEN) vaccine
SponsorU.S. Army Medical Research and Development Command
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DEN vaccine F17

What is DEN vaccine F17?

DEN vaccine F17 is a Biologic drug developed by U.S. Army Medical Research and Development Command.

Who makes DEN vaccine F17?

DEN vaccine F17 is developed by U.S. Army Medical Research and Development Command (see full U.S. Army Medical Research and Development Command pipeline at /company/u-s-army-medical-research-and-development-command).

Is DEN vaccine F17 also known as anything else?

DEN vaccine F17 is also known as Live attenuated tetravalent dengue (DEN) vaccine.

What development phase is DEN vaccine F17 in?

DEN vaccine F17 is in Phase 1.

Related